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Background: An outbreak of serotype 1 invasive pneumococcal disease (IPD) occurred in Central Australia from
October 2010 to the latter part of 2012. Surveillance of serotype 1 carriage was conducted to determine
epidemiological features of asymptomatic carriage that could potentially be driving the outbreak.
Methods: 130 patients and accompanying persons presenting at Alice Springs Hospital Emergency Department
consented to nasopharyngeal swab (NPS) collection. NPS were processed by standard methods, including culture,
pneumococcal lytA quantitative real-time PCR, serotype 1-specific real-time PCR and multi-locus sequence
typing (MLST).
Results: Pneumococcal carriage was detected in 16% of participants. Carriage was highest in the under 10 year
olds from remote communities surrounding Alice Springs (75%). Four NPS were positive for serotype 1 DNA by
PCR; 3 were also culture-positive for serotype 1 pneumococci. Serotype 1 isolates had atypical colony morphology
on primary culture. All serotype 1 carriers were healthy children 5 to 8 years of age from remote communities.
By MLST, serotype 1 isolates were ST306, as were IPD isolates associated with this outbreak.
Conclusions: During an outbreak of serotype 1 ST306 IPD, carriage of the outbreak strain was detected in 3% NPS
collected. All carriers were healthy children 5 to 8 years of age.
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Pneumococcal (Streptococcus pneumoniae) disease is a
major contributor to morbidity and mortality worldwide
[1]. The WHO estimates that pneumococcal disease is
responsible for at least 1 million child deaths annually
[2]. Greater than 90% of these deaths occur in developing
countries where few children have access to pneumococcal
vaccines [3].
More than 90 different pneumococcal serotypes exhibit-
ing a wide range of epidemiological profiles have been
reported [4]. Pneumococcus serotype 1 is one of the* Correspondence: Jana.lai@menzies.edu.au
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reproduction in any medium, provided the orseven most common serotypes globally that cause IPD
[3]. Serotype 1 is ranked among the top four serotypes
in Africa, Asia and Latin America, which experience
the highest IPD burden [3]. Serotype 1 is commonly as-
sociated with outbreaks of IPD and can cause severe
disease including meningitis, complicated pneumonia
and pulmonary empyema [5].
Certain serotypes are commonly found in the majority
of nasopharyngeal carriage isolates from children [4].
Serotype 1 is rarely found in asymptomatic nasopharyn-
geal (NP) carriage, even in areas of high serotype 1 IPD
[6,7]. This is believed to be a function of its low density
and brief duration in the nasopharynx. During epidemics
of serotype 1 IPD, the probability of detecting asymp-
tomatic carriage is increased, as demonstrated by reportsThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[9,10].
Young Indigenous children in remote communities in
Australia have pneumococcal carriage rates of approxi-
mately 80%, and high rates of IPD, pneumonia and otitis
media, related to endemic overcrowding [11]. In 2001,
a 7-valent pneumococcal conjugate vaccine (PCV7) was
included in the Northern Territory (NT) Childhood
Vaccination Schedule for Indigenous and high-risk non-
Indigenous infants as a 2, 4 and 6 month schedule with
23-valent pneumococcal polysaccharide vaccine (PPV23)
recommended as the booster dose for Indigenous children
at 18 months of age. PCV7 (2, 4, 6 months, with no
booster) was introduced nationally for all infants in 2005.
On 1st October 2009 the NT introduced 10-valent
pneumococcal Haemophilus influenzae protein D conju-
gate vaccine (PHiD-CV10), offering additional protection
against serotypes 1, 5 and 7F as a 2, 4, 6 and 18 month
schedule for all children. Since 1999, PPV23, which offers
protection against serotype 1, has been recommended
for Indigenous adults who are 15 years of age or older,
and in 2005 for all Australians 65 years of age or those
medically at risk [12-14].
In Australia there have been documented cases of
serotype 1 isolation from NP carriage samples [5,15,16].
During a serotype 1 IPD outbreak in 1991 in Central
Australia, serotype 1 upper respiratory tract carriage was
reported in 13 of 75 (17.3%) hospitalised children [15].
Serotype 1 NP carriage in Indigenous communities was
also reported in northern regions of the Northern Ter-
ritory in 1992–1993, 2002–2003, and 2005 [5,16].
These studies reported asymptomatic NP carriage of
serotype 1 in children; the cases were not associated
with serotype 1 IPD outbreaks. In the 2002 surveillance
study, serotype 1 was carried by 13% (21/158) children
under 11 years [5].
In November 2010, Alice Springs and surrounding
areas, known as Central Australia, serviced by the Alice
Springs Hospital, reported a 65% increase in IPD cases
compared to the previous year [17]. IPD cases were
primarily serotype 1 Sequence Type (ST) 306. The out-
break continued until the latter part of 2012. Through
the peak until end of 2011, there had been a total of 69
cases of serotype 1 ST306 IPD, with 84% of cases Indi-
genous, median age 10 years (range 3–61 years) [17]
and mean age 18 years (SD 16–21) (pers. Comm. H.
Cook). A further 18 cases were identified in 2012 [17].
The aim of this study was to identify the potential sero-
type 1 carriage reservoir in the region.
Methods
Population
This study was in response to a request for surveillance
of pneumococcal carriage in Central Australia during anoutbreak of IPD. Central Australia has a geographical
area of 830 000 square kilometres and a population of
over 46 000, with a population of 28 000 in the town of
Alice Springs. Alice Springs Hospital is the main hospital
for Central Australia. The target population in this study
was the residents of Central Australia.
Collection and participation criteria
During March 18–21, 2011, nasopharyngeal swabs (NPS)
were collected from consenting participants presenting
to or visiting the Alice Springs Hospital Emergency
Department. Those meeting the following criteria were
excluded: Triage 1 and 2 patients, (requiring urgent or
immediate care); apparently under the influence of
alcohol or other drugs; having special needs; in police
custody; and very recent arrivals (tourists) into Central
Australia. Signed informed consent was obtained for
collection of a single nasopharyngeal swab and for
access to individual pneumococcal vaccination data.
Consent included options for testing swabs for pneu-
mococcus alone, and/or laboratory storage for future eth-
ically approved studies of respiratory pathogens. Place of
residence and date of birth were also collected. The
Central Australian Human Research Ethics Committee
provided a waiver for this surveillance study as it was
in response to a disease outbreak requiring a timely
response.
Sample collection
Once consent was obtained, NPS were collected using
rayon tipped swabs on flexible aluminium shafts. The
quality of the sample was recorded as good (inserted
into the nasopharynx for 5 seconds), fair (inserted briefly
into the nasopharynx), poor (external nares) or sample
collected with the swab after nose blowing into a tissue
[18]. Nose blowing is not a standard sample collection
method but offers an alternative specimen collection for
children who refuse a nose swab and who have visible
nasal discharge [18]. Swabs were immediately placed
into 1ml of skim milk tryptone glucose glycerol broth
(STGGB) [19] and frozen on dry ice. After each day of
collection, frozen samples were transferred to a liquid
nitrogen vapour shipper for storage and transport within
6 days to a −80°C freezer at the Menzies School of
Health Research laboratory in Darwin NT, Australia.
Pneumococcal culture
Following WHO guidelines for the routine laboratory
culture of pneumococcus [19], 10 μl of the 1 ml NPS in
STGGB were cultured and grown to determine the pres-
ence of pneumococcus by colony morphology, optochin
susceptibility, the Phadebact© pneumococcus test and
positive Quellung omniserum reaction. At least two
presumptive pneumococcal colonies were selected for
Lai et al. BMC Infectious Diseases 2013, 13:409 Page 3 of 7
http://www.biomedcentral.com/1471-2334/13/409serotyping, including morphologically distinct colonies.
Pneumococcal serotyping of isolates was by Quellung
method [19]. Antibiotic susceptibility followed the cali-
brated dichotomous susceptibility (CDS) method for
oxacillin (1 μg), penicillin (0.5 μg), tetracycline (30 μg),
sulfamethoxazole/trimethoprim (25 μg), erythromycin
(5 μg), chloramphenicol (30 μg) and azithromycin (15 μg)
[20]. Isolates non-susceptible to penicillin or azithromycin
had minimum inhibitory concentration (MIC) determined
using E-tests (BioMerieux, France). Using the Clinical and
Laboratory Standards Institute (CLSI) guidelines, penicil-
lin breakpoints for intermediate resistance and resistance
were > 0.06 ― ≤ 2 μg/ml and >2 μg/ml respectively [21].
Azithromycin breakpoints for intermediate resistance
and resistance were > 0.25 - ≤ 0.5 μg/ml and > 0.5 μg/ml
respectively [21]. Presumptive non-capsular pneumococci
(NCSpn) were identified as optochin sensitive, Phade
bact© pneumococcus test negative, bile soluble and
Quellung Omni serum negative.DNA extraction from NPS samples
DNA was extracted from 100 μl aliquots of each NPS
using a QIAamp 96 DNA blood kit (Qiagen, Germany)
following enzymatic lysis as described previously [22].
The DNA was used in both the probe-based quantitative
real-time PCR (qPCR) targeting lytA and the serotype 1
detection by real-time PCR as described below. For the
qPCR 2 μl of sample was used in each reaction and for
serotype 1 real-time PCR 1 μl of sample was used in
each reaction.Pneumococcal detection and estimation of load by qPCR
Probe-based qPCR targeting lytA was used for detection
of pneumococcus and estimation of pneumococcal load
in NPS as previously described using forward (5′-TC
TTACGCAATCTAGCAGATGAAGC-3′) and reverse (5′-
GTTGTTTGGTTGGTTATTCGTGC-3′) primers and
probe (5′- [6-FAM]-TTTGCCGAAAACGCTTGATACA
GGG- [TAMRA]-3′), with product size of 101 bp [22,23].
All samples were run in duplicate in a Rotor-Gene 6000
real-time thermocycler (Corbett Research). Five pneumo-
coccal DNA standards (reference strain ATCC49619) from
9 to 90,000 genome copies per reaction were included
in each run along with multiple template controls of
common respiratory pathogens. The limit of detection
for this assay is 8.92 cells, equivalent to 4460 cells/ml.
Successful qPCR assays had a standard curve correl-
ation coefficient and efficiency of > 0.99 and > 0.86
respectively. All samples and standards were run in
duplicate and required to amplify within 0.5 cycles.
Any samples that did not fit the acceptability criteria
were re-tested up to two times before being rejected
and considered negative for pneumococcal DNA.Serotype 1 detection real-time PCR
For detection of serotype 1 from NPS samples, serotype
1 primers described for multiplex PCR serotyping by Pai
et al. (2006), using forward (5′-CTCTATAGAATGGAG
TATATAAACTATGGTTA-3′) and reverse (5′-CCAAAG
AAAATACTAACATTATCACAATATTGGC-3′) primers,
with product size of 280 bp [24] were used in a SYBR-
based (Bioline, London) real-time PCR. For the positive
control a high concentration (8.92 × 104 copies/μl) and
low concentration (8.92 copies/μl) of pneumococcal sero-
type 1 DNA was used. Cycling conditions were as follows;
50°C 2 mins, 95°C 10 mins, 45 cycles of 94°C for 30 s, 54°C
for 30 s, 68°C for 60 s. A melt curve was generated for
each reaction and any curve that deviated from the
control melt curve was considered negative for serotype
1 DNA. Melt-curve analysis was done between 50-99°C,
with 1°C each step with weight of 90 s pre-melt condition-
ing on first step and 5 s wait for each step thereafter. Both
SYBR-based real-time and melt-curve analysis were done
in a Rotor-Gene 6000 real-time thermocycler (Corbett
Research).
Serotype 1 multilocus sequence typing (MLST)
A single serotype 1 isolate from each of the serotype 1 cul-
ture positive NPS was analysed by MLST using modified
primers as per Marsh et al. [21]. PCR products were
sequenced, using the forward and reverse primers from
each PCR (Macrogen, South Korea). Analysis of results
was done using DNA Star (DNA star, USA); final se-
quences were submitted to the MLST database (www.
mlst.net).
Statistical analysis
All results were entered and analysis of results was done
using STATA version 11.
Results
In total, 130 people consented to participate in the
study; approximately 40% of people approached refused
to participate. The age range of the participants was 1–
77 years (mean 37.2 years, SD ±20.5 years); 25% were 10
years of age and younger, 6% were 11–18 years of age,
and 69% were 19–77 years. Twenty-seven participants
were from 13 remote communities surrounding Alice
Springs and 103 were from Alice Springs.
Pneumococcal carriage
Twenty-one NPS (21/130, 16.2%) were positive by culture
for capsular pneumococci and nineteen NPS (19/130,
14.6%) were positive for pneumococcal lytA DNA. By
culture, carriage was highest (9/12, 75.0%) in the age
group of 10 years and younger from remote communi-
ties, compared with 47.6% (10/21) of children in Alice
Springs (Table 1). Pneumococcal carriage in the greater








culture positive (95% CI)
Pneumococcus serotype 1
PCR positive (95% CI)
Residence
Alice Springs 103/130 (79.2%) 10/103 (9.7%) (5, 17) 11/103 (10.7%) (5, 18) 0/103 (0.0%) 0/103 (0.0%)
Remote Communities 27/130 (20.8%) 11/27 (40.7%) (22, 61) 8/27 (29.6%) (14, 50) 3/27 (11.1%) (2, 29) 4/27 (14.8%) (4, 34)
Alice Springs
≤10years 21/103 (20.4%) 10/21 (47.6%) (26, 70) 10/21 (47.6%) (26, 70) 0/21 (0.0%) 0/21 (0.0%)
>10years 82/103 (79.6%) 0/82 (0.0%) 1/82 (1.2%) (0.03, 7) 0/82 (0.0%) 0/82 (0.0%)
Remote
Communities
≤10years 12/27 (44.4%) 9/12 (75.0%) (43, 95) 8/12 (66.7%) (18,62) 3/12 (25.0%) (5, 57) 4/12 (33.3%) (10, 65)
>10years 15/27 (55.6%) 2/15 (13.3%) (2, 40) 0/15 (0.0%) (0, 22) 0/15 (0.0%) 0/15 (0.0%)
Data also include number of participants positive for pneumococcus by both culture and molecular methods.
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residents, and 13.3% (2/15) for residents of remote
communities.
Pneumococcus serotype 1 carriage
Three samples were culture positive for serotype 1, with
high semi-quantitative counts. In these samples, there
was no detection of co-carriage with other serotypes
following selection of two colonies and any that were
morphologically distinct. On culture, serotype 1 isolates
had an atypical morphology in that they were small and
dry or large, crenelated and dry.
DNA extracts from all samples were screened for the
presence of pneumococcus serotype 1 DNA. The three
samples positive by culture for serotype 1 were also
positive by PCR, and a further serotype 1 DNA positive
sample. This sample was culture positive for 10A but
not for serotype 1 despite screening 100 colonies on the
plate using the Quellung reaction. All serotype 1 PCR
positive samples were from children 5 to 8 years of age
from three remote communities in Central Australia.
MLST analysis was undertaken on serotype 1 isolates
acquired by microbiological culture from the three cul-
ture-positive children. The isolates had the same allelic
profile by MLST, corresponding to sequence type (ST) 306.
Pneumococcal conjugate vaccination status
Of the 130 participants sampled, there were 33 children
who were 10 years or younger. Twenty-one children 10
years and younger had received a primary course of
PCV7, with 16 of those also receiving a booster of PPV23.
Four children had received a primary course of PHiD-CV
and 8 children received a combination of PCV7 and
PHiD-CV for their primary course. Two children did
not provide consent or the data were missing. Of the
four children positive for serotype 1 carriage, one did
not provide consent to access their immunisation re-
cords, one had missing immunisation records and twohad received a primary course of PCV7 with a PPV23
booster. The two adults positive for pneumococcal car-
riage both had received two doses of PPV23.
Pneumococcal serotype, antimicrobial resistance,
and load
Fifteen different serotypes of capsular pneumococci were
identified from the 21 pneumococcus positive swabs
(Figure 1). Multiple serotype carriage was observed in 1
swab, which had serotypes 15C and 35B.
Penicillin intermediate resistance and azithromycin
resistance was detected in 7 of 22 (31.8%; serotypes
16F, 19A, 19F, 31) and 5 of 22 (22.7%; serotypes 16F,
17F, 19A, 22F, 31) isolates respectively. Serotype 1 isolates
were susceptible to both antibiotics.
qPCR failed to detect 4 culture-positive swabs, while
culture failed to detect 2 PCR-positive swabs. The sero-
types that were detected by culture in these PCR-negative
samples were 6C, 19A, 33A and 33F. The range of
pneumococcal DNA concentration in the NPS samples
detected by qPCR was 1.51x103 to 7.15x106 cells/ml.
Non-capsular pneumococci (NCSpn)
Eight samples were positive by culture for NCSpn (6.1%),
and co-carriage with capsular pneumococci was detected
in 5 samples (serotypes 6C, 16F, 19F, 23B and 31). Seven
of 8 NCSpn were non-susceptible to penicillin; six
displayed intermediate resistance and one was resistant.
Seven of eight NCSpn were resistant to azithromycin.
Discussion
Pneumococcal carriage was detected in 16% (21/130)
participants. Serotype 1 carriage was detected in four of
33 participants (12%) under the age of 10 years; three by
culture and a fourth by real-time PCR. Overall pneumo-
coccal carriage rates were also highest in this age group
(19/33; 58%). Children from remote communities had
the highest carriage at 75% (9/12). Of interest, all serotype
Figure 1 Distribution of pneumococcal serotypes detected in culture, by age group; <10years and ≥10years. PCV7 has serotypes 4, 6B,
9V, 14, 18C, 19F, and 23F (covers 4.8% positive swabs), PHiD-CV also has serotypes 1,5, 7F (covers 19.1% positive swabs), PCV13 also has serotypes
3, 6A, 19A, (covers 33.3% of positive swabs) and PPV23 has serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20,
22F, 23F and 33F (covers 52.4% of swabs).
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remote communities. The three samples with culture-
confirmed serotype 1 had high semi-quantitative counts
and no co-colonisation with other serotypes detected.
Serotype 1 is included in the 10-valent pneumococcal
conjugate vaccine, PHiD-CV, but not in PCV7. All
participants who received at least one dose of PHiD-CV,
had no serotype 1 carriage. Among the four participants
positive for serotype 1, two had either missing immunisa-
tion records or no consent to access their records and the
other two had received a full course of PCV7 with a
booster of PPV23.
All serotype 1 isolates were both penicillin and azithro-
mycin susceptible, whereas isolates of serotypes 16F, 17F,
19A, 19F, 22F, 31, and NCSpn displayed resistance to one
or both of these antibiotics. All serotype 1 isolates from
culture-positive samples were MLST ST306. IPD isolates
associated with this outbreak were also ST306 [17]. This
ST has been reported throughout Europe [6], from sterile
and non-sterile sites.
The serotype 1 isolates detected in primary culture,
and after our routine method of freezing in STGGB for
transport and storage, had an atypical morphology.
Serotype 1 isolates were small and dry or large, crenelated
and dry, even though they were grown in a humid 37°C
CO2 incubator. Upon passage, the colony morphology
changed to a smooth, typical pneumococcal morphology.
Serotype 1 is reported to be rarely detected in carriage,
even in areas of high serotype 1 IPD [6,7]. This is primarily
believed to be due to low density and short duration ofcolonisation [4]; however atypical morphology may lead
to missed observations of carriage, and our finding fur-
ther emphasises the importance of considering atypical
pneumococcal colony morphologies in pneumococcal
carriage studies.
In previous studies investigating serotype 1 carriage,
there was limited documentation of co-colonisation with
other serotypes; a single study reported 34% simultaneous
colonisation with other pneumococcal serotypes [5]. In
the current study, co-colonisation was not detected by
selecting two colonies per culture plate and any that
were morphologically distinct. The three NPS serotype
1 positive samples had three colonies each identified as
serotype 1; however one of the serotype 1 DNA positive
samples was positive in culture for serotype 10A. It is
uncertain whether serotype 1 has a propensity to colonise
with certain serotypes due to the limited data we have
and also from the scarce literature available.
In this study there were more pneumococcal culture
positive samples than pneumococcal qPCR positive sam-
ples. This discrepancy may be due to the lower limit of
detection of culture (100 cells/ml) compared with qPCR
(4460 cells/ml). We previously reported a higher sensitiv-
ity for PCR (likely due to detection of metabolically
inactive cells), despite the disparity in limit of detection
[22]. However, this was in high density carriage populations.
In low density carriage populations the disparity in limit
of detection may become more pronounced.
A limitation of this study was the low number of partici-
pants and the restriction to a single hospital emergency
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consistent with the age of past serotype 1 colonisation
in this population, where serotype 1 colonisation was
detected in children 12 years of age and younger [5,15].
A larger prevalence study including remote communities
in the region may have allowed more definitive conclu-
sions on the age of risk of colonisation with serotype 1,
and improve data on the pneumococcal serotype distri-
bution in this population. Longitudinal sampling would
have provided a more comprehensive picture of the
epidemiology of serotype 1 carriage during the out-
break, including the movement of serotype 1 through
the communities.
Conclusions
Nasopharyngeal swabbing during a Central Australia out-
break of serotype 1 IPD (mean age 18 years) identified
asymptomatic carriers of serotype 1 as children under
the age of 10 years living in remote communities. Serotype
1 carriage was not detected in PHiD-CV vaccinated partic-
ipants. Serotype 1 isolates had atypical colony morphology
on primary culture, which could result in missed identifi-
cation. Because newer formulations of pneumococcal
vaccines include serotype 1, populations that have received
them may have a lower prevalence of asymptomatic
carriage of pneumococcus serotype 1, resulting in a
lower a lower incidence of serotype 1 IPD. It would be
useful to conduct more extensive carriage studies to
further understand the population biology of pneumo-
coccus, which may be able to inform outbreak control
strategies.
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